Galapagos and AbbVie Aim to Compete with Vertex in Cystic Fibrosis Market
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 10 (Table of Contents)
Published: 10 Oct-2013
DOI: 10.3833/pdr.v2013.i10.1984 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In the second deal between the companies in the space of 2 years, AbbVie and Galapagos have partnered to discover, develop and commercialise novel oral therapies for cystic fibrosis (CF) that target the main mutations in the cystic fibrosis transmembrane regulator (CFTR) protein...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS